By Kunal Das July 15 (Reuters) – Shares of Celcuity fell nearly 19% in morning trading on Wednesday, as the delayed commercial launch of its newly approved breast cancer drug and label concerns
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)